Scholar Rock Holding Corporation's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Company leadership is renewed; directors set strategy and oversee management decisions affecting shareholder value.
Quarterly earnings show how much money the company made or lost, helping investors track progress.
Quarterly performance data and business updates help investors understand recent company progress.
FDA approval of this spinal muscular atrophy drug could generate revenue; decision expected by late September 2026.
Accurate financial numbers matter; the company fixed a calculation error in 2025 earnings.
Annual financial statements show total yearly performance; investors use this to evaluate company health.
Annual earnings data and management updates help investors assess yearly performance and future plans.
Stocky reads Scholar Rock Holding Corporation's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Scholar Rock Holding Corporation's most recent tracked filing was a 8-K on 5 Jun 2026: Stockholders elect four directors to three-year terms.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.